GSK_ Annual_Report_2021-22

Notes to the Consolidated Financial Statements for the year ended March 31, 2022 259 NOTE 59 : Additional Information (i) The Group does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property. (ii) The Group has not traded or invested in Crypto currency or Virtual Currency during the financial year. (iii) The Group has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries. (iv) The Group has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Group shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries. (v) The Group does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961). Note 60 : Additional information as required by Paragraph 2 of the general instructions for the Preparation of Consolidated Financial Statements under Division II of Schedule III to the Companies Act, 2013 ( ` in lakhs ) Name of the entity in the Group Net Assets, i.e., total assets minus total liabilities * Share in profit or loss Share in other comprehensive income Share in total comprehensive income As % of consolidated net assets Amount As % of consolidated profit or loss Amount As % of consolidated other comprehensive income Amount As % of consolidated total comprehensive income Amount As at March 31, 2022 As at March 31, 2022 Year ended March 31, 2022" Year ended March 31, 2022 Year ended March 31, 2022 Year ended March 31, 2022 Year ended March 31, 2022" Year ended March 31, 2022 Parent GlaxoSmithKline Pharmaceuticals Limited 98.93% 2634,33.78 99.31% 1683,08.47 100.00% (1,84.53) 99.31% 1681,23.94 Subsidiary Indian Biddle Sawyer Limited 1.07% 28,61.80 0.69% 11,63.46 0.00% - 0.69% 11,63.46 Total 100.00% 2662,95.58 100.00% 1694,71.93 100.00% (1,84.53) 100.00% 1692,87.40